Design and synthesis of new fused carbazole-imidazole derivatives as anti-diabetic agents: In vitro α-glucosidase inhibition, kinetic, and in silico studies

被引:37
|
作者
Adib, Mehdi [1 ]
Peytam, Fariba [1 ]
Shourgeshty, Reihaneh [1 ]
Mohammadi-Khanaposhtani, Maryam [2 ]
Jahani, Mehdi [1 ]
Imanparast, Somaye [3 ,4 ]
Faramarzi, Mohammad Ali [3 ,4 ]
Larijani, Bagher [5 ]
Moghadamnia, Ali Akbar [2 ,6 ]
Esfahani, Ensieh Nasli [7 ]
Bandarian, Fatemeh [7 ]
Mahdavi, Mohammad [5 ]
机构
[1] Univ Tehran, Coll Sci, Sch Chem, POB 14155-6455, Tehran, Iran
[2] Babol Univ Med Sci, Hlth Res Inst, Cellular & Mol Biol Res Ctr, Babol Sar, Iran
[3] Univ Tehran Med Sci, Fac Pharm, Dept Pharmaceut Biotechnol, Tehran, Iran
[4] Univ Tehran Med Sci, Biotechnol Res Ctr, Tehran, Iran
[5] Univ Tehran Med Sci, Endocrinol & Metab Res Ctr, Endocrinol & Metab Clin Sci Inst, Tehran, Iran
[6] Babol Univ Med Sci, Dept Pharmacol, Fac Med Sci, Babol Sar, Iran
[7] Univ Tehran Med Sci, Diabet Res Ctr, Endocrinol & Metab Clin Sci Inst, Tehran, Iran
关键词
Carbazole; Imidazole; alpha-Glucosidase; In silico study; In vitro evaluation; EFFICIENT; POTENT;
D O I
10.1016/j.bmcl.2019.01.012
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Twenty three fused carbazole-imidazoles 6a-w were designed, synthesized, and screened as new alpha-glucosidase inhibitors. All the synthesized fused carbazole-imidazoles 6a-w were found to be more active than acarbose (IC50 = 750.0 +/- 1.5 mu M) against yeast alpha-glucosidase with IC50 values in the range of 74.0 +/- 0.7-298.3 +/- 0.9 mu M. Kinetic study of the most potent compound 6v demonstrated that this compound is a competitive inhibitor for alpha-glucosidase (K-i value = 75 mu M). Furthermore, the in silico studies of the most potent compounds 6v and 6o confirmed that these compounds interacted with the key residues in the active site of alpha-glucosidase.
引用
收藏
页码:713 / 718
页数:6
相关论文
共 50 条
  • [1] Design and synthesis of new benzylidene-quinazolinone hybrids as potential anti-diabetic agents: In vitro α-glucosidase inhibition, and docking studies
    Khalifa, Mohamed M.
    Sakr, Helmy M.
    Ibrahim, Albaraa
    Mansour, Ahmed M.
    Ayyad, Rezk R.
    JOURNAL OF MOLECULAR STRUCTURE, 2022, 1250
  • [2] In silico design, synthesis and characterization of quercetin derivatives as anti-diabetic agents
    Sasikala, M.
    Mohan, S.
    Geetha, M.
    Nisha, E.
    Narmadha, N.
    Nagarajan, A.
    INDIAN JOURNAL OF HETEROCYCLIC CHEMISTRY, 2024, 34 (04) : 513 - 520
  • [3] Biscoumarin-1,2,3-triazole hybrids as novel anti-diabetic agents: Design, synthesis, in vitro α-glucosidase inhibition, kinetic, and docking studies
    Asgari, Mohammad Sadegh
    Mohammadi-Khanaposhtani, Maryam
    Kiani, Mitra
    Ranjbar, Parviz Rashidi
    Zabihi, Ebrahim
    Pourbagher, Roghayeh
    Rahimi, Rahmatollah
    Faramarzi, Mohammad Ali
    Biglar, Mahmood
    Larijani, Bagher
    Mahdavi, Mohammad
    Hamedifar, Haleh
    Hajimiri, Mir Hamed
    BIOORGANIC CHEMISTRY, 2019, 92
  • [4] Diaryl azo derivatives as anti-diabetic and antimicrobial agents: synthesis, in vitro, kinetic and docking studies
    Tahir, Tehreem
    Shahzad, Mirza Imran
    Tabassum, Rukhsana
    Rafiq, Muhammad
    Ashfaq, Muhammad
    Hassan, Mubashir
    Kotwica-Mojzych, Katarzyna
    Mojzych, Mariusz
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2021, 36 (01) : 1509 - 1520
  • [5] Stereoselective Synthesis of Highly Functionalized Aminobenzothiazole-Fused Spirooxindole Derivatives: in silico and in vitro Anti-Diabetic Studies
    Nivetha, Narayanasamy
    Patil, Shashank M.
    Ramu, Ramith
    Sreenivasa, Swamy
    Velmathi, Sivan
    SYNTHESIS-STUTTGART, 2023, 55 (24): : 4145 - 4162
  • [6] Design and synthesis of 4,5-diphenyl-imidazol-1,2,3-triazole hybrids as new anti-diabetic agents: in vitro α-glucosidase inhibition, kinetic and docking studies
    Asgari, Mohammad Sadegh
    Mohammadi-Khanaposhtani, Maryam
    Sharafi, Zeinab
    Faramarzi, Mohammad Ali
    Rastegar, Hossein
    Esfahani, Ensieh Nasli
    Bandarian, Fatemeh
    Rashidi, Parviz Ranjbar
    Rahimi, Rahmatollah
    Biglar, Mahmood
    Mandavi, Mohammad
    Larijani, Bagher
    MOLECULAR DIVERSITY, 2021, 25 (02) : 877 - 888
  • [7] Design and synthesis of 4,5-diphenyl-imidazol-1,2,3-triazole hybrids as new anti-diabetic agents: in vitro α-glucosidase inhibition, kinetic and docking studies
    Mohammad Sadegh Asgari
    Maryam Mohammadi-Khanaposhtani
    Zeinab Sharafi
    Mohammad Ali Faramarzi
    Hossein Rastegar
    Ensieh Nasli Esfahani
    Fatemeh Bandarian
    Parviz Ranjbar Rashidi
    Rahmatollah Rahimi
    Mahmood Biglar
    Mohammad Mahdavi
    Bagher Larijani
    Molecular Diversity, 2021, 25 : 877 - 888
  • [8] Design, synthesis and in vitro α-glucosidase inhibition of novel dihydropyrano[3,2-c]quinoline derivatives as potential anti-diabetic agents
    Nikookar, Hamideh
    Mohammadi-Khanaposhtani, Maryam
    Imanparast, Somaye
    Faramarzi, Mohammad Ali
    Ranjbar, Parviz Rashidi
    Mahdavi, Mohammad
    Larijani, Bagher
    BIOORGANIC CHEMISTRY, 2018, 77 : 280 - 286
  • [9] Design and synthesis of novel quinazolinone-1,2,3-triazole hybrids as new anti-diabetic agents: In vitro α-glucosidase inhibition, kinetic, and docking study
    Saeedi, Mina
    Mohammadi-Khanaposhtani, Maryam
    Pourrabia, Parvaneh
    Razzaghi, Nima
    Ghadimi, Reza
    Imanparast, Somaye
    Faramarzi, Mohammad Ali
    Bandarian, Fatemeh
    Esfahani, Ensieh Nasli
    Safavi, Maliheh
    Rastegar, Hossein
    Larijani, Bagher
    Mandavi, Mohammad
    Akbarzadeh, Tahmineh
    BIOORGANIC CHEMISTRY, 2019, 83 : 161 - 169
  • [10] Synthesis, a-glucosidase Inhibition, in silico Pharmacokinetic, and Docking Studies Of Thieno[2,3-b]Quinoline-Acetamide Derivatives as New Anti-Diabetic Agents
    Mohammadi-Khanaposhtani, Maryam
    Noori, Milad
    Valizadeh, Yousef
    Dastyafteh, Navid
    Ghomi, Minoo Khalili
    Mojtabavi, Somayeh
    Faramarzi, Mohammad Ali
    Hosseini, Samanesadat
    Biglar, Mahmood
    Larijani, Bagher
    Rastegar, Hossein
    Hamedifar, Haleh
    Mirzazadeh, Roghieh
    Mahdavi, Mohammad
    CHEMISTRYSELECT, 2022, 7 (44):